Company facts
- Industry
- Laboratory Analytical Instruments
- Headquarters
- Santa Clara, California
- Most recent report
- 8-K, filed Sep 8, 2026
- Incorporated
- Delaware
- Filings on record
- 1,008+ filings
- On EDGAR
- CIK 1090872
- Fiscal year ends
- October
- Filer status
- Large accelerated filer
Financials 8 of 40
News 8 of 108
Prospectuses and Registrations 8 of 23
- S-4 Registration statement for a merger or exchange Sep 1, 2026
- S-3ASR Automatic shelf registration Sep 1, 2026
- 424B5 Prospectus supplement for an offering Sep 6, 2024
- FWP Free writing prospectus Sep 4, 2024
- 424B5 Prospectus supplement for an offering Sep 4, 2024
- S-3ASR Automatic shelf registration Sep 3, 2024
- 424B5 Prospectus supplement for an offering Mar 5, 2021
- FWP Free writing prospectus Mar 3, 2021
Proxies 8 of 25
- DEFA14A Extra proxy material Feb 6, 2026
- DEF 14A Proxy statement for a shareholder vote Feb 6, 2026
- PRE 14A Preliminary proxy statement Jan 23, 2026
- DEFA14A Extra proxy material Feb 21, 2025
- DEFA14A Extra proxy material Jan 31, 2025
- DEF 14A Proxy statement for a shareholder vote Jan 31, 2025
- PRE 14A Preliminary proxy statement Jan 14, 2025
- DEF 14A Proxy statement for a shareholder vote Feb 2, 2024
Ownership 8 of 797
- 144 Notice of a proposed sale of restricted stock Sep 4, 2026
- 4 Insider reported a trade Jun 29, 2026
- 3 Insider reported their initial holding Jun 5, 2026
- 4 Insider reported a trade Jun 5, 2026
- 4 Insider reported a trade Jun 2, 2026
- 144 Notice of a proposed sale of restricted stock May 29, 2026
- 4 Insider reported a trade May 21, 2026
- 4 Insider reported a trade May 12, 2026
Other 8 of 15
- SD Conflict minerals disclosure May 29, 2026
- ARS Annual report sent to shareholders Feb 6, 2026
- SD Conflict minerals disclosure May 27, 2025
- ARS Annual report sent to shareholders Jan 31, 2025
- SD Conflict minerals disclosure May 28, 2024
- ARS Annual report sent to shareholders Feb 2, 2024
- SD Conflict minerals disclosure May 24, 2023
- ARS Annual report sent to shareholders Feb 3, 2023
What to read: Jul 2026 10-Q
SECSift found 2 of 11 sections worth reading, with 4 positive, 6 notable, and 0 negative flags.
Financial Statements (Item 1)
Core financial results, acquisition, and debt issuance; all material.Management's Discussion (Item 2)
Many specific financial results, acquisitions, debt, restructuring, tariff impacts.Positive- Net revenue up 8% in Q3 and 9M 2026; net income $362M (Q3) and $1,006M (9M).
- Cash from operations increased to $1,064M in 9M 2026 from $1,014M in 9M 2025.
- Gross margin up 4ppts in Q3 to 55.5% and 2ppts in 9M to 54.0% vs prior year.
- Operating margin up 3ppts in Q3 to 23.6% and 1ppt in 9M to 21.7% vs prior year.
Notable- Acquired Biocare for $950M net cash on June 24, 2026, expanding pathology portfolio.
- Issued $600M 4.90% senior notes due 2032 on June 25, 2026.
- Two restructuring plans (FY25 $109M, FY26 $15M) aim for combined $120-130M annual savings.
- Tariff refunds contributed ~1ppt to Q3 operating margin improvement.
- Inventory days on hand rose to 120 from 107 due to strategic tariff-mitigation purchases.
What changed: Jul 2026 vs. Apr 2026
About 8% of A's Jul 2026 10-Q is new information. 35 paragraphs were added, 235 changed, and 46 removed. Below are the most important lines SECSift identified.
New
- New FY26 restructuring plan recorded $15 million expense in the three and nine months ended July 31, 2026. Item 1
- Added new Exhibits 4.1, 4.2, 4.3 for 4.900% Senior Notes due 2032 issued June 2026. Item 6
- New FASB guidance on environmental credits effective FY2029; being evaluated for impact on financials. Item 1
Changed
- Total debt rose to $3.9B from $3.4B; senior notes rose to $3.9B from $3.3B as of July 31, 2026. Item 1A
- Weighted average price paid rose to $127.24 from $118.90 per share. Item 2
- Remaining buyback authorization fell to $1,654 million from $1,732 million. Item 2
- Changed from no receivable to submitting additional IEEPA tariff refund claims; recoverability uncertain. Item 1
- Exhibit 10.1 replaced prior 10.1 (Transition Agreement) and 10.2 (Letter of Terms) with Deferred Compensation Plan effective 2024. Item 6
- Principal Accounting Officer signature changed from Rodney Gonsalves to Timothy C. Downs. Item 6
- Submitted additional IEEPA tariff refund claims; recognized net benefit of 1 ppt to Q3 operating margin. Item 2
- Total shares repurchased rose to 612,270 from 550,000 in the quarterly period ended July 31, 2026. Item 2
Removed
- Removed Exhibits 3.1 (Certificate of Incorporation) and 3.2 (Bylaws) that were included previously. Item 6
- Removed exception for U.S. federal government-funded customers from the prior quarter's outlook. Item 2
- Removed prior Exhibit 10.2 (Letter of Terms for Adam Elinoff Short Term Assignment). Item 6
Everything here comes from Agilent Technologies, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour. SECSift analysis was completed on Sep 1, 2026, from the 10-Q for Jul 2026.